Global Non-PVC IV Bags Market By Product Type (Single Chamber, Multi Chamber), By Material (Ethylene Vinyl Acetate, Polypropylene, Co-polyester ether, Others), By Content (Frozen Mixture, Liquid Mixture) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
- Published date: March 2023
- Report ID: 16486
- Number of Pages: 206
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
The Global Non-PVC IV Bags Market size is expected to be worth around USD 5095.06 million by 2032 from USD 1731 million in 2022, growing at a CAGR of 11.4 during the forecast period 2023 to 2032.
The major factors of this industry trend include a rising demand to prevent errors such as incorrect dose delivery and increased demand for advanced IV container technology. Fagron Sterile Services US – a 503B outsourcing facility, announced that intravenous therapy (IV), bags had been added to its product portfolio in March 2021.
The traditional IV container has issues such as drug-packaging materials interactions and problems in transporting, handling, and disposing of the containers. These problems can be avoided by using a Non-PVC IV bags. Accordingly, the demand for the Non-PVC bags market growth is expected to soar during the forecasted period.
Global Non-PVC IV Bags Market Scope:
Product Type Analysis
In 2021, the single chamber segment was responsible for the largest portion 65.2%. Single-chamber IV bags are still very popular and will continue to be so in the future, as IV bags will start with other IV containers. Non-PVC materials have accelerated the use of plastic bags to replace glass containers. These benefits include ease of transportation and disposal. You can also use intravenous solutions such as drip bags, irrigation fluids, and sterile water. The segment will grow over the forecast period because single-chamber bags will be more widely used.
The fastest growth is expected for the multi-chambered segment during the forecast period. For intravenous treatment, multi-chambered IV bags are preferable when multiple medications must be administered. Multi-Chamber IV Bags are made from non-PVC film and have fast seal properties. These bags are widely used in the healthcare sector for emergency situations. Because they can be opened at a lower time than other IV bags, they make it easier for the pharmaceutical industry to use them.
Aside from their high stability, high-pressure agility and outstanding transparency, toughness, thermal sealing, and reusable nature, multi-chamber IV bags are widely used in pharmaceuticals. The main factor behind the rise of multi-chambered container use in various materials like parenteral nutrition, drug reconstitution, and customized product offerings is the multi-chambered market.
Material Analysis
The largest share was held by Ethylene Vinyl Acetate, which accounted for around 34.85%. It is expected that the key segment scope will continue to grow significantly over the forecast period. EVA, the most common PVC alternative, was the market leader in 2020. EVA is expected to be used extensively in blood banks and when freezing mixtures are stored. The forecast period will see a significant increase in segment share due to growing recognition and increased demand for blood and blood component storage. Additionally, parenteral nutrition therapy is increasing in popularity and the high incidence of chronic kidney diseases is expected to drive demand for EVA bags.
The co-polyester ether section is projected to experience the fastest growth in the period under study. Co-polyester ether has several benefits. These include durability, transparency, and chemical resistance. They can also withstand radiation and autoclave sterilization. Copolyesterether is stronger when it is combined with other materials like polypropylene, polyolefin, and other resins. The Excel Epoxymer is a key future trend in the evolution of co-polyester ether’s use in pharmaceutical packaging. Companies that are involved in the development and production of these combinations include Eastman Chemical Company (Eastman Chemical Company), Sealed Air Corporation, B. Braun Melsungen AG, and Sealed Air Corporation.
Content Analysis
The largest segment of liquid mixtures was around 78.7% in 2021. Some key factors that contributed to this large share are the use of IV drips and innovative designs. There is a growing demand for IV containers that are more resistant to low temperatures and have greater security than standard PVC in blood banks vertically. Major players in this market are working hard to increase their production capabilities and increase their market share. Grifols began production in Brazil’s new blood-collection plant in 2019 with a limit exceeding 10 million blood-collection bags per year.
Кеу Маrkеt Ѕеgmеntѕ
By Product Type
- Multi-Chamber
- Single Chamber
By Material
- Copolyester ether
- Polypropylene
- Ethylene Vinyle Acetate
- Other Materials
By Content
- Liquid Mixture
- Frozen Mixture
Market Dynamics:
A growing number of people are interested in oncology treatments. These therapeutic agents are susceptible to interactions with plasticizers, which can cause them to turn into dangerous agents. These discordances can be reduced by using containers deprived of plasticizers. These bags are made out of ethylene–vinyl-acetate and polypropylene. Many firms are now using plasticizer-free and biocompatible materials to replace polyvinyl chloride. B. Braun has spent USD 500.00 million over the past five years on innovative ways of providing DEHP and PVC-free product lines. Through the replacement of PVC and glass containers, the availability and development of modern materials in different forms are forecast to increase demand for non-PVC IV Bags.
Market growth can also be supported by the strong presence of local manufacturers in the global markets, strict regulations against the disposal of PVC, and the improvement in healthcare infrastructure in emerging economies. Technology advancements in service quality as well as an increased number worldwide of hospitals are other factors that support the growth of the global non-PVC IV bags market.
The human body suffers from cancer treatment. The body is also affected by cancer treatments, such as GI dysfunction, physical obstructions, and ulcers. These factors all prevent the body from naturally obtaining nutrition from food. The patients must be administered externally. In recent years, the demand for IV bags has been increasing as cancer has become more common. According to the World Health Organization(WHO), cancer is the second leading cause of demise worldwide.
The World Health Organization (WHO) estimates that cancer caused 9.6 million deaths worldwide in 2018. According to the American Cancer Society (ACS), more than 1.75 million cases of new cancers were detected in America in 2019. Based on data from Cancer Research U.K. 36,7000 new prevalence of cancer cases were reported annually in the U.K. Each year this is the best indicator of the potential growth of the IV solutions industry dynamics.
PVC IV bags are a growing concern in medical fields. Phthalates leaching from the equipment can pose a danger to both human health as well as the environment. Incineration has produced toxic HCL, which is a result of the disposal of PVC products. Acid rainfall is further affected by this. Building IV bags, made from PVC-free material with moisture-barrier properties, thermal stability, and environmentally-friendly disposal.
Regional Market Analysis
North America held the largest market share of the 2021 market growth. It is projected to grow at an 11.2 % CAGR during the forecast period. There are strict regulations in America that aim to improve patient safety. This has led to increased demand for non-PVC IV containers. These containers provide safe, effective patient care without exposing patients to harm. As stomach cancer is more common, IV bags are in high demand.
The American Cancer Society has estimated that approximately 27,600 cases of will be diagnosed in the U.S. with stomach cancer in 2020. In addition, 11,010 would be affected by the disease. Because stomach cancer patients cannot eat food through their mouths, they must rely on complete parenteral care for their survival and dietary needs. This could lead to a rise in demand for ethylene-vinyl alcohol (EVA) IV bags. In return, market growth is expected. In this region, there is also the possibility of a rise in the use of innovative drug delivery systems as well as technological innovations.
Asia Pacific is expected to have the highest CAGR for the forecasted duration. The competitive landscape of local manufacturers is promoting international demand by selling products at affordable prices, increasing foreign direct investments, and rapid improvement to healthcare industry infrastructures, such as a rising number of hospitals and clinics, all have a significant impact on the industry’s growth.
Key Regions and Countries Covered іn thе Rероrt:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Spain
- Rest of Europe
- APAC
- China
- Japan
- South Korea
- India
- Rest of Asia-Pacific
- Latin America
- Brazil
- Argentina
- Rest of South America
- MEA
- GCC
- South Africa
- Israel
- Rest of MEA
The market’s key players play a role in developing strategies, such as partnerships, mergers and acquisitions, and the launch of new products. Baxter was granted FDA approval in July 2019 for Myxredlin. It is the only ready-to-use insulin for IV Infusion.
In order to produce the most advanced products possible, major players are investing heavily in research and development. China’s first “non-PVC solid fluid double chamber bag for ceftazidime/sodium chloride injection” certification has been granted to the Group. There are several prominent market players in this global market for non-PVC IV bags are:
Маrkеt Кеу Рlауеrѕ:
- Angiplast Pvt. Ltd.
- Alfa Laboratories
- Baxter International
- Braun Melsungen AG
- B. Braun Medical Inc.
- Huaren Pharmaceutical Co.,
- Pfizer, Inc. (Hospira)
- Fresenius Kabi AG
- Gen Eco-Technologies Co., Ltd
- JW Life Science
- Jiangxi Sanxin Medtec Co., Ltd.
- Kraton Corporation
- Otsuka Holdings Co., Ltd.
- Renolit SE
- Sartorius AG
- Shanghai Solve Care Co., Ltd.
- Shanghai Xin Gen Eco-Technologies Co.
- PolyCine GmbH
- Technoflex
- Sippex
- Pharmaceutical Solutions
- Vioser
- ICU Medical
- Well Pharma
- Other Key Players
For the Non-PVC IV Bags Market research study, the following years have been considered to estimate the market size:
Attribute Report Details Market Size in 2022
USD 1731 million
Growth Rate
11.4%
Forecast Value in 2032
USD 5095.06 million
Historical Years
2016-2020
Base Year
2021
Estimated Year
2022
Short Term Projection Year
2028
Projected Year
2023
Long Term Projection Year
2032
Report Coverage
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
Regional Scope
North America, Europe, Asia-Pacific, South America, Middle East & Africa
Country Scope
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
Frequently Asked Questions (FAQ)
What is the Global Non-PVC IV Bag Market size is expected in 2032?The expected market size of the Global Non-PVC IV Bag Market size is USD 5095.06 million.
What is CAGR of Non-PVC IV Bags market during forecast period?The CAGR of Non-PVC IV Bags Market is growing at a CAGR of 11.4 during the forecast period.
- Angiplast Pvt. Ltd.
- Alfa Laboratories
- Baxter International Inc Company Profile
- B. Braun Melsungen AG Company Profile
- B. Braun Medical Inc.
- Huaren Pharmaceutical Co.,
- Pfizer, Inc. (Hospira)
- Fresenius Kabi AG
- Gen Eco-Technologies Co., Ltd
- JW Life Science
- Jiangxi Sanxin Medtec Co., Ltd.
- Kraton Corporation
- Otsuka Holdings Co., Ltd.
- Renolit SE
- Sartorius AG
- Shanghai Solve Care Co., Ltd.
- Shanghai Xin Gen Eco-Technologies Co.
- PolyCine GmbH
- Technoflex
- Sippex
- Pharmaceutical Solutions
- Vioser
- ICU Medical
- Well Pharma
- Other Key Players
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |